Aptose Biosciences Inc. (APTO)

2.29
NASDAQ : Health Technology
Prev Close 2.36
Day Low/High 2.27 / 2.43
52 Wk Low/High 1.57 / 3.20
Avg Volume 445.70K
Exchange NASDAQ
Shares Outstanding 55.44M
Market Cap 134.58M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Aptose To Release Second Quarter Ended June 30, 2019 Financial Results And Hold Conference Call On August 6, 2019

Aptose To Release Second Quarter Ended June 30, 2019 Financial Results And Hold Conference Call On August 6, 2019

SAN DIEGO and TORONTO, July 23, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc.

Aptose Doses First CLL Patient In Phase 1 Study Of CG-806 And Doses Third Cohort In Phase 1 Study Of APTO-253

Aptose Doses First CLL Patient In Phase 1 Study Of CG-806 And Doses Third Cohort In Phase 1 Study Of APTO-253

 - CG-806 oral non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML  -  - APTO-253 MYC inhibitor being developed for the treatment of AML and MDS   - SAN DIEGO and TORONTO, July 16,...

Aptose Reports Results For The Fourth Quarter And Year Ended December 31, 2017

Aptose Reports Results For The Fourth Quarter And Year Ended December 31, 2017

Conference Call and Webcast at 5pm EDT Today

OHSU And Aptose Present CG'806 Preclinical Data At ASH 59th Annual Meeting

OHSU And Aptose Present CG'806 Preclinical Data At ASH 59th Annual Meeting

CG'806 reveals broad and potent single agent activity, and enhanced activity when combined with Bcl-2 or BET inhibitors, against AML and CLL patient samples

Aptose Presents New Preclinical Data On CG'806 Pan-FLT3/pan-BTK Inhibitor At ASH 59th Annual Meeting

Aptose Presents New Preclinical Data On CG'806 Pan-FLT3/pan-BTK Inhibitor At ASH 59th Annual Meeting

Data elucidate unique ability of CG'806 to kill a broad range of AML cells by suppressing multiple pathways, to overcome resistance caused by bone marrow stromal cells, and to act synergistically with other agents

Aptose Reports Results For The Third Quarter Ended September 30, 2017

Aptose Reports Results For The Third Quarter Ended September 30, 2017

Conference Call and Webcast at 5pm EST Today

Aptose Enters Into $15.5 Million Common Shares Purchase Agreement With Aspire Capital Fund, LLC

Aptose Enters Into $15.5 Million Common Shares Purchase Agreement With Aspire Capital Fund, LLC

Aptose Provides Corporate Update Highlights

Preclinical Data On Aptose Biosciences FLT3/BTK Inhibitor CG'806 Presented At AACR Hematologic Malignancies Meeting

Data support superiority of CG'806 relative to competitive agents against AML driven by diverse mutated forms of FLT3

OHSU And Aptose Present CG'806 Preclinical Data Demonstrating Potent Activity Against Patient Samples At AACR Hematologic Malignancies Meeting

Data support superiority of CG'806 relative to select competitive agents